Results 21 to 30 of about 920 (164)

CINtec PLUS Immunocytochemistry as a Tool for the Cytologic Diagnosis of Glandular Lesions of the Cervix Uteri [PDF]

American Journal of Clinical Pathology, 2012
Abstract Cytologic findings of glandular lesions of the cervix uteri are often difficult to evaluate. We studied the usefulness of CINtec PLUS p16/Ki-67 double stain (mtm laboratories, Heidelberg, Germany) for the diagnosis of glandular lesions.
Ravarino A, Nemolato S, Macciocu E, FRASCHINI, MATTEO, Senes G, Faa G, Negri G.   +6 more
openaire   +2 more sources

p16/Ki67 dual stain triage versus cytology in primary human papillomavirus‐based cervical cancer screening with limited genotyping

Journal of Medical Virology, Volume 95, Issue 11, November 2023., 2023
Abstract The introduction of primary human papillomavirus (HPV) cervical cancer screening requires the implementation of an appropriate triage strategy that will be effective in detecting high‐grade cervical disease without losing diagnostic specificity.
Martyna Trzeszcz, Maciej Mazurec, Robert Jach, Karolina Mazurec, Izabela Kotkowska‐Szeps, Magdalena Kania, Mariola Wantuchowicz, Jolanta Wasowska, Monika Duczek‐Polakiewicz, Patrycja Rozmus, Joanna Streb, Agnieszka Halon   +11 more
wiley   +1 more source

Durable and dramatic response to checkpoint inhibition combined with COX-2 inhibitor celecoxib in a patient with p16+ metastatic sinonasal undifferentiated carcinoma: A case study. [PDF]

Cancer Rep (Hoboken)
Abstract Background Sinonasal undifferentiated carcinoma (SNUC) is an exceedingly rare head and neck malignancy. No consensus exists on treatment for metastatic disease. Case A 56‐year‐old female was diagnosed with SNUC after endorsing sinus congestion, diplopia, and right orbital pain.
Trinh JQ, Acosta C, Easwar A, Galamaga R, Tan A.   +4 more
europepmc   +2 more sources

A pilot study of camrelizumab with docetaxel and cisplatin for the first line treatment in recurrent/metastatic oral squamous cell carcinoma

MedComm, Volume 4, Issue 4, August 2023., 2023
This phase Ib trial enrolled patients diagnosed recurrent/metastatic oral squamous cell carcinoma (R/M OSCC) with previously untreated and PD‐L1 positive. Our data suggest that camrelizumab with docetaxel/cisplatin was well tolerable and had favorite efficacy in PD‐L1‐positive patients with R/M OSCC.
Houyu Ju, Dongliang Wei, Yunteng Wu, Yang Liu, Qi Ding, Mengyu Rui, Zongyu Fan, Yanli Yao, Jingzhou Hu, Guoxin Ren   +9 more
wiley   +1 more source

The Accuracy of p16/Ki-67 and HPV Test in the Detection of CIN2/3 in Women Diagnosed with ASC-US or LSIL. [PDF]

PLoS ONE, 2015
The objective of this study was to compare the accuracies of double staining for p16/Ki-67 and the molecular test for high-risk HPV (hr-HPV) to identify high-grade cervical intraepithelial neoplasia (CIN2/CIN3) in women with cervical cytology of atypical
Júlio C Possati-Resende, José H T G Fregnani, Ligia M Kerr, Edmundo C Mauad, Adhemar Longatto-Filho, Cristovam Scapulatempo-Neto   +5 more
doaj   +1 more source

The specificity and patterns of staining in human cells and tissues of p16INK4a antibodies demonstrate variant antigen binding [PDF]

, 2013
The validity of the identification and classification of human cancer using antibodies to detect biomarker proteins depends upon antibody specificity. Antibodies that bind to the tumour-suppressor protein p16INK4a are widely used for cancer diagnosis and
A Melck, A Okamoto, AM Groeger, BC Soares de Sa, BE Gould Rotheberg, C Michaloglou, C Pilon, CQ Zhu, David Andrew Gunn, DE Marra, Dudley Ferdinando, F Haller, F Haller, G Volgareva, H Lin, HA McKenzie, Hong Wu, J Chen, J Lukas, Jeffrey Pawlikowski, JW Rocco, K Cuschieri, K Nilsson, M Dray, M Schutte, Magdalena Sawicka, Peter David Adams, R Klaes, S Pavey, Sophia N. Karagiannis, SS Wang, Stephen Wilson, WH Liggett Jr, William Parish, Y Cheng   +34 more
core   +3 more sources

CINtec R PLUS (Ki-67 e p16INK4a) vs Métodos Biomoleculares em casos de Lesão Intraepitelial Baixo Grau do colo do útero [PDF]

, 2014
Mariana Cruz da Costa
core   +3 more sources

Human papillomavirus and p53 status define three types of vulvar squamous cell carcinomas with distinct clinical, pathological, and prognostic features

Histopathology, Volume 83, Issue 1, Page 17-30, July 2023., 2023
Currently, all VSCC are treated similarly, irrespective of HPV and p53 status. Our findings suggest that in the future, the treatment of VSCC might be tailored in accordance with these molecular subgroups (HPV‐associated VSCC, HPV‐independent VSCC with wildtype p53, HPV‐independent VSCC with mutated p53), given their different prognosis and behaviour ...
Nuria Carreras‐Dieguez, Adela Saco, Marta del Pino, Lorena Marimon, Ricardo López del Campo, Carolina Manzotti, Pere Fusté, Clàudia Pumarola, Aureli Torné, Adriana Garcia, Natalia Rakislova   +10 more
wiley   +1 more source

Time trends in prevalence of p16 positivity and combined HPV/p16 positivity in a large cohort of Danish vulvar cancer patients

International Journal of Cancer, Volume 152, Issue 11, Page 2424-2432, 1 June 2023., 2023
What's new? A subset of vulvar cancers is caused by high‐risk human papillomavirus (HPV), which primarily exerts its oncogenic effect through upregulation of tumor suppressor protein p16. How the proportion of HPV‐driven vulvar cancers has changed over time remains largely unexplored.
Christina Louise Rasmussen, Louise T. Thomsen, Louise Baandrup, Maria Benedicte Franzmann, Alexander K. Kjær, Lise Grupe Larsen, Else Mejlgaard Madsen, Nadia Margeth Villena Salinas, Doris Schledermann, Birgitte Hjelm Winberg, Dorthe Ørnskov, Marianne Waldstrøm, Susanne K. Kjær   +12 more
wiley   +1 more source

Six-pattern p53 interpretation in 1293 vulvar squamous cell carcinomas: inter-pathologist variation and pattern distribution according to p16 status. [PDF]

Histopathology
Six‐pattern immunohistochemical p53 assessment of 1,293 vulvar squamous cell carcinomas by eight pathologists showed 66.7% concordance across all six patterns, increasing to 86.9% when dichotomized to wild‐type versus mutated. The high interobserver agreement supports the clinical robustness of the six‐pattern p53 framework, with most discrepancies ...
Kaderly Rasmussen EL, Kjær SK, Larsen LG, Mejlgaard E, Franzmann MB, Kjær AK, Salinas NV, Schledermann D, Frederiksen K, Hansen T, Winberg BH, Waldstrøm M, Baandrup L.   +12 more
europepmc   +2 more sources